Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INMB 
INmune Bio Inc (INMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INMB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.25
1 Year Target Price $5.25
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.88% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.06M USD | Price to earnings Ratio - | 1Y Target Price 5.25 |
Price to earnings Ratio - | 1Y Target Price 5.25 | ||
Volume (30-day avg) 5 | Beta 0.98 | 52 Weeks Range 1.89 - 10.50 | Updated Date 08/14/2025 |
52 Weeks Range 1.89 - 10.50 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.4267 | Actual -0.341 |
Profitability
Profit Margin - | Operating Margin (TTM) -79430% |
Management Effectiveness
Return on Assets (TTM) -55.08% | Return on Equity (TTM) -168.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35135260 | Price to Sales(TTM) 1361.17 |
Enterprise Value 35135260 | Price to Sales(TTM) 1361.17 | ||
Enterprise Value to Revenue 702.71 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 26585300 | Shares Floating 17087940 |
Shares Outstanding 26585300 | Shares Floating 17087940 | ||
Percent Insiders 24.61 | Percent Institutions 29.43 |
Upturn AI SWOT
INmune Bio Inc
Company Overview
History and Background
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing therapies targeting the innate immune system to treat diseases. Founded to address unmet needs in neurodegenerative diseases and cancer, it has advanced multiple novel therapies into clinical trials.
Core Business Areas
- Neuroinflammation: Focuses on developing therapies like XPro1595 to treat neurodegenerative diseases such as Alzheimer's by targeting soluble TNF.
- Innate Immunity: Developing therapies to modulate the innate immune system for cancer treatment. Specifically, DN-TNF for treating minimal residual disease (MRD) in cancer.
Leadership and Structure
The leadership team includes Raymond Tesi, MD, CEO, and David Moss, CFO. The company operates with a structure focusing on research and clinical development, supported by business development and finance functions.
Top Products and Market Share
Key Offerings
- XPro1595: A selective inhibitor of soluble TNF (sTNF) being developed for Alzheimer's disease and other neuroinflammatory conditions. Market share is currently 0% as it is in clinical trials. Competitors include Biogen (ADU) with Leqembi, Eisai (ESALY) with Leqembi (co-developed with Biogen), and Eli Lilly (LLY) with Donanemab.
- DN-TNF: A Dominant Negative TNF (DN-TNF) immunotherapy designed to eliminate tumor-promoting myeloid cells. Currently in clinical trials targeting minimal residual disease (MRD) in cancer. Market share is currently 0%. Competitors include companies developing CAR-T cell therapies, such as Novartis (NVS) and Gilead Sciences (GILD).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, with many companies developing therapies for neurodegenerative diseases and cancer. The market is characterized by high risk and high reward, driven by innovation and regulatory approvals.
Positioning
INmune Bio is positioned as an innovator in innate immunity therapeutics, focusing on modulating the immune system to treat diseases. Its competitive advantage lies in its proprietary DN-TNF and sTNF targeting technology.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease is estimated to be billions of dollars annually. The TAM for cancer therapies targeting MRD is also substantial, potentially exceeding billions, but is contingent on successful clinical trials and regulatory approval. INmune Bio is positioning itself to capture a significant portion of these markets by addressing unmet medical needs.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting innate immunity
- Proprietary DN-TNF and sTNF targeting technology
- Experienced leadership team
- Multiple clinical-stage programs
Weaknesses
- Limited financial resources compared to larger competitors
- High clinical trial risk
- Reliance on successful clinical trial outcomes
- No currently marketed products
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Orphan drug designation for specific indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- ESALY
- LLY
- NVS
- GILD
Competitive Landscape
INmune Bio faces intense competition from larger, well-established pharmaceutical companies. Its competitive advantage lies in its novel therapeutic approach and proprietary technology, but it must successfully navigate clinical trials and regulatory approvals to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing clinical programs, not revenue generation.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on clinical trial progress.
Recent Initiatives: Recent initiatives include advancing XPro1595 in Alzheimer's clinical trials and DN-TNF in cancer MRD trials.
Summary
INmune Bio is a clinical-stage biotech company with a novel approach to treating diseases by targeting the innate immune system. The company's strength lies in its innovative technology and experienced team, but it faces significant risks associated with clinical trials and competition. Successful clinical trial outcomes are essential for future growth. Its high risk high reward proposition makes it a company to watch, but requires caution.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INmune Bio Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2019-02-04 | Co-Founder, President, CEO, Chief Medical Officer & Chairman Dr. Raymond Joseph Tesi M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.inmunebio.com |
Full time employees 13 | Website https://www.inmunebio.com | ||
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.